22 completed. 13 Phase 1, 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 3 |
Follow darapladib: new trials by email Literature Review of darapladib trials Research Report on darapladib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) Darapladib - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 9 | 2014-02-26 | 2017-05-15 |
| Darapladib China PK darapladib 160mg - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 24 | 2013-10-23 | 2017-05-15 |
| Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects Darapladib, Midazolam - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 26 | 2013-06-19 | 2017-05-15 |
| Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848). Darapladib, Diltiazem - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 36 | 2013-05-14 | 2017-07-13 |
| To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers Rosuvastatin 10 mg, Darapladib 160 mg - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 18 | 2012-12-17 | 2017-07-26 |
| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment Darapladib 160 mg - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 16 | 2012-10-29 | 2017-07-26 |
| A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema darapladib, placebo - Retinopathy, Diabetic | Phase 2 | Completed | GlaxoSmithKline | 54 | 2012-02-01 | 2016-11-21 |
| SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033) darapladib, placebo - Coronary Heart Disease | Completed | GlaxoSmithKline | 28855 | 2011-10-01 | 2014-11-03 | |
| Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects darapladib - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 24 | 2010-07-01 | 2017-07-26 |
| Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans darapladib, placebo - Endothelial Dysfunction | Phase 3 | Completed | Mayo Clinic | 70 | 2010-02-04 | 2017-04-18 |
| The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial Darapladib 160 mg, Placebo, Standard Therapy - Acute Coronary Syndrome | Phase 3 | Completed | GlaxoSmithKline | 13026 | 2009-12-01 | 2017-08-10 |
| The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial Darapladib, Placebo - Atherosclerosis | Phase 3 | Completed | GlaxoSmithKline | 15828 | 2008-12-01 | 2017-08-10 |
| A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848 darapladib - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 20 | 2008-09-01 | 2016-11-16 |
| A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients SB480848 40mg EC Tablet, SB480848 80mg EC Tablet, SB480848 160mg EC Tablet - Atherosclerosis | Phase 2 | Completed | GlaxoSmithKline | 107 | 2008-08-26 | 2018-01-12 |
| A Study With Darapladib to Collect Tolerability Information SB-480848 (darapladib) - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 2 | 2008-05-01 | 2016-11-04 |
| Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects- SB-480848 (Darapladib) - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 18 | 2008-01-01 | 2016-11-03 |
| A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men Darapladib (SB480848) - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 18 | 2007-07-01 | 2016-12-05 |
| Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart Darapladib - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 72 | 2006-12-01 | 2016-10-28 |
| A Study To Determine The Effect Of SB-480848 On Asthma SB 480848, tablets - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 67 | 2006-08-01 | 2016-12-05 |
| Integrated Biomarker And Imaging Study - 2 SB-480848, SB-480848 matching placebo - Atherosclerosis | Phase 2 | Completed | GlaxoSmithKline | 336 | 2005-11-10 | 2018-03-20 |
Showing 20 of 22. Sign in to see all of them.
Atherosclerosis (20) · Cardiovascular Diseases (3) · Coronary Disease (3) · Acute Coronary Syndrome (2) · Heart Diseases (2) · Asthma (1) · Coronary Artery Disease (1) · Coronary Vasospasm (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Retinopathy (1) · Dyslipidemias (1) · Renal Insufficiency (1)
GlaxoSmithKline (21) · Mayo Clinic (1)
United States (14) · Germany (6) · Denmark (5) · Netherlands (5) · Australia (4) · France (4) · Japan (4) · Spain (4) · Argentina (3) · Belgium (3) · Bulgaria (3) · Canada (3) · China (3) · Czechia (3) · Hungary (3)
Amir Lerman, MD (1)
PMID 18436114, PMID 21982651, PMID 22496275, PMID 24586490, PMID 24678955, PMID 24721691, PMID 25173516, PMID 26465780, PMID 26672609, PMID 26920728, PMID 27329448, PMID 27811204, PMID 28077384, PMID 28735759, PMID 28797349, PMID 28862971, PMID 28912210, PMID 28960596, PMID 29018021, PMID 29066452, PMID 29306475, PMID 30371283, PMID 30897999, PMID 32375553, PMID 32480059, PMID 33439866, PMID 34562103, PMID 35060389, PMID 35861814, PMID 39390990
R01AG031750 (1), R01HL092954 (1)